Lundbeck reiterates outlook as net misses estimate – MarketWatch

Lundbeck reiterates outlook as net misses estimate
MarketWatch
-But Lundbeck's 2012 results will be hampered by the expiry of its patent for escitalopram in the US in March, which already resulted in a revenue decline for its antidepressant drug Lexapro in the first quarter. -The patent expiry led to a 55% drop in …

and more

Leave a Reply